Diagnostic Ability of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prostate Cancer and Clinically Significant Prostate Cancer in Equivocal Lesions: A Systematic Review and Meta-Analysis
BackgroundDynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) now has been used to diagnose prostate cancer (PCa). Equivocal lesions are defined as PIRADS category 3 or a Likert scale of 1 to 5 category 3 lesions. Currently, there are no clear recommendations for the management of these l...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.620628/full |
| _version_ | 1828961653457158144 |
|---|---|
| author | Jing Zeng Qingqing Cheng Dong Zhang Meng Fan Changzheng Shi Changzheng Shi Liangping Luo Liangping Luo |
| author_facet | Jing Zeng Qingqing Cheng Dong Zhang Meng Fan Changzheng Shi Changzheng Shi Liangping Luo Liangping Luo |
| author_sort | Jing Zeng |
| collection | DOAJ |
| description | BackgroundDynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) now has been used to diagnose prostate cancer (PCa). Equivocal lesions are defined as PIRADS category 3 or a Likert scale of 1 to 5 category 3 lesions. Currently, there are no clear recommendations for the management of these lesions. This study aimed to estimate the diagnostic capacity of DCE-MRI for PCa and clinically significant prostate cancer (csPCa) in equivocal lesions.Materials and methodsTwo researchers searched PubMed, Embase and Web of Science to identify studies that met our subject. We searched for articles that mention the accuracy of the diagnosis of DCE-MRI for PCa or csPCa in equivocal lesions and used histopathological results as the reference standard. We used a tool (the Quality Assessment of Diagnostic Accuracy Studies-2 tool) to evaluate the quality of the studies that we screened out. Meta-regression was used to explore the reasons for heterogeneity in results.ResultsTen articles were eventually included in our study. The sensitivity, specificity and 95% confidence intervals (CI) for DCE-MRI in diagnosing csPCa were 0.67 (95% CI, 0.56–0.76), 0.58 (95% CI, 0.46–0.68). The sensitivity and specificity and 95% CI for DCE-MRI in diagnosing PCa were 0.57 (95% CI, 0.46–0.68), 0.58 (95% CI, 0.45–0.70). The areas under the curve (AUC) of DCE-MRI were 0.67 (95% CI, 0.63–0.71) and 0.60 (95% CI, 0.55–0.64) while diagnosing csPCa and PCa. Through meta-regression, we found that study design, magnetic field strength, the definition of csPCa, and the scoring system were the sources of heterogeneity.ConclusionThe results of our study indicate that the role of DCE-MRI in equivocal lesions may be limited. |
| first_indexed | 2024-12-14T09:49:13Z |
| format | Article |
| id | doaj.art-87f4a1497b6147a7aaecf96028b76aab |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-14T09:49:13Z |
| publishDate | 2021-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-87f4a1497b6147a7aaecf96028b76aab2022-12-21T23:07:33ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-02-011110.3389/fonc.2021.620628620628Diagnostic Ability of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prostate Cancer and Clinically Significant Prostate Cancer in Equivocal Lesions: A Systematic Review and Meta-AnalysisJing Zeng0Qingqing Cheng1Dong Zhang2Meng Fan3Changzheng Shi4Changzheng Shi5Liangping Luo6Liangping Luo7Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, ChinaMedical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, ChinaMedical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, ChinaMedical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, ChinaMedical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, ChinaEngineering Research Center of Medical Imaging Artificial Intelligence for Precision Diagnosis and Treatment, Guangzhou, ChinaMedical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, ChinaEngineering Research Center of Medical Imaging Artificial Intelligence for Precision Diagnosis and Treatment, Guangzhou, ChinaBackgroundDynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) now has been used to diagnose prostate cancer (PCa). Equivocal lesions are defined as PIRADS category 3 or a Likert scale of 1 to 5 category 3 lesions. Currently, there are no clear recommendations for the management of these lesions. This study aimed to estimate the diagnostic capacity of DCE-MRI for PCa and clinically significant prostate cancer (csPCa) in equivocal lesions.Materials and methodsTwo researchers searched PubMed, Embase and Web of Science to identify studies that met our subject. We searched for articles that mention the accuracy of the diagnosis of DCE-MRI for PCa or csPCa in equivocal lesions and used histopathological results as the reference standard. We used a tool (the Quality Assessment of Diagnostic Accuracy Studies-2 tool) to evaluate the quality of the studies that we screened out. Meta-regression was used to explore the reasons for heterogeneity in results.ResultsTen articles were eventually included in our study. The sensitivity, specificity and 95% confidence intervals (CI) for DCE-MRI in diagnosing csPCa were 0.67 (95% CI, 0.56–0.76), 0.58 (95% CI, 0.46–0.68). The sensitivity and specificity and 95% CI for DCE-MRI in diagnosing PCa were 0.57 (95% CI, 0.46–0.68), 0.58 (95% CI, 0.45–0.70). The areas under the curve (AUC) of DCE-MRI were 0.67 (95% CI, 0.63–0.71) and 0.60 (95% CI, 0.55–0.64) while diagnosing csPCa and PCa. Through meta-regression, we found that study design, magnetic field strength, the definition of csPCa, and the scoring system were the sources of heterogeneity.ConclusionThe results of our study indicate that the role of DCE-MRI in equivocal lesions may be limited.https://www.frontiersin.org/articles/10.3389/fonc.2021.620628/fullDCE-MRIdynamic contrast-enhanced magnetic resonance imagingprostate cancerclinically significant prostate cancerequivocal lesions |
| spellingShingle | Jing Zeng Qingqing Cheng Dong Zhang Meng Fan Changzheng Shi Changzheng Shi Liangping Luo Liangping Luo Diagnostic Ability of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prostate Cancer and Clinically Significant Prostate Cancer in Equivocal Lesions: A Systematic Review and Meta-Analysis Frontiers in Oncology DCE-MRI dynamic contrast-enhanced magnetic resonance imaging prostate cancer clinically significant prostate cancer equivocal lesions |
| title | Diagnostic Ability of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prostate Cancer and Clinically Significant Prostate Cancer in Equivocal Lesions: A Systematic Review and Meta-Analysis |
| title_full | Diagnostic Ability of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prostate Cancer and Clinically Significant Prostate Cancer in Equivocal Lesions: A Systematic Review and Meta-Analysis |
| title_fullStr | Diagnostic Ability of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prostate Cancer and Clinically Significant Prostate Cancer in Equivocal Lesions: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Diagnostic Ability of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prostate Cancer and Clinically Significant Prostate Cancer in Equivocal Lesions: A Systematic Review and Meta-Analysis |
| title_short | Diagnostic Ability of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prostate Cancer and Clinically Significant Prostate Cancer in Equivocal Lesions: A Systematic Review and Meta-Analysis |
| title_sort | diagnostic ability of dynamic contrast enhanced magnetic resonance imaging for prostate cancer and clinically significant prostate cancer in equivocal lesions a systematic review and meta analysis |
| topic | DCE-MRI dynamic contrast-enhanced magnetic resonance imaging prostate cancer clinically significant prostate cancer equivocal lesions |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.620628/full |
| work_keys_str_mv | AT jingzeng diagnosticabilityofdynamiccontrastenhancedmagneticresonanceimagingforprostatecancerandclinicallysignificantprostatecancerinequivocallesionsasystematicreviewandmetaanalysis AT qingqingcheng diagnosticabilityofdynamiccontrastenhancedmagneticresonanceimagingforprostatecancerandclinicallysignificantprostatecancerinequivocallesionsasystematicreviewandmetaanalysis AT dongzhang diagnosticabilityofdynamiccontrastenhancedmagneticresonanceimagingforprostatecancerandclinicallysignificantprostatecancerinequivocallesionsasystematicreviewandmetaanalysis AT mengfan diagnosticabilityofdynamiccontrastenhancedmagneticresonanceimagingforprostatecancerandclinicallysignificantprostatecancerinequivocallesionsasystematicreviewandmetaanalysis AT changzhengshi diagnosticabilityofdynamiccontrastenhancedmagneticresonanceimagingforprostatecancerandclinicallysignificantprostatecancerinequivocallesionsasystematicreviewandmetaanalysis AT changzhengshi diagnosticabilityofdynamiccontrastenhancedmagneticresonanceimagingforprostatecancerandclinicallysignificantprostatecancerinequivocallesionsasystematicreviewandmetaanalysis AT liangpingluo diagnosticabilityofdynamiccontrastenhancedmagneticresonanceimagingforprostatecancerandclinicallysignificantprostatecancerinequivocallesionsasystematicreviewandmetaanalysis AT liangpingluo diagnosticabilityofdynamiccontrastenhancedmagneticresonanceimagingforprostatecancerandclinicallysignificantprostatecancerinequivocallesionsasystematicreviewandmetaanalysis |